| Bid | 12.75 |
| Market Cap | 184.86M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 119.39 |
| PE Ratio (ttm) | 0.11 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 12.92 |
| Volume | 10,145 |
| Avg. Volume (20D) | 70,627 |
| Open | 13.72 |
| Previous Close | 12.74 |
| Day's Range | 12.71 - 13.77 |
| 52-Week Range | 10.80 - 18.95 |
| Beta | undefined |
About INBX
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate ...
Analyst Forecast
According to 3 analyst ratings, the average rating for INBX stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 111.43% from the latest price.
2 months ago · seekingalpha.com
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique PlatformINBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing p...